UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation

Blood, 2000-02, Vol.95 (4), p.1502-1505

2000

Volltextzugriff (PDF)

Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor

Cancer gene therapy, 2015-02, Vol.22 (2), p.95-100

2015

Volltextzugriff (PDF)

T-Cell Immunotherapy for Adenoviral Infections of Stem-Cell Transplant Recipients

Annals of the New York Academy of Sciences, 2005-12, Vol.1062 (1), p.104-115

2005

Volltextzugriff (PDF)

Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines

Current topics in microbiology and immunology, 2001, Vol.258, p.221

2001

Volltextzugriff (PDF)

Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo

Nature medicine, 2005-02, Vol.11 (2), p.130-137

2005

Volltextzugriff (PDF)

Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals

The Journal of immunology (1950), 2002-01, Vol.168 (2), p.909-918

2002

Volltextzugriff (PDF)

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

Cancer gene therapy, 2004-02, Vol.11 (2), p.81-91

2004

Volltextzugriff (PDF)

Immunotherapy for Hodgkin's disease

Annals of hematology, 2002, Vol.81 Suppl 2, p.S39-S42

2002

Volltextzugriff (PDF)

Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15

Cytotherapy (Oxford, England), 2003, Vol.5 (3), p.231-240

2003

Volltextzugriff (PDF)

Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes

Transplantation, 2004-09, Vol.78 (5), p.755-757

2004

Volltextzugriff (PDF)

Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients

Transplantation, 2001-09, Vol.72 (6), p.1078

2001

Volltextzugriff (PDF)

Options for T-cell based therapies

Vox sanguinis, 2004-07, Vol.87 (s2), p.230-234

2004

Volltextzugriff (PDF)

Immune therapy for EBV infections after hemopoietic stem-cell transplant

Cytotherapy (Oxford, England), 2002-09, Vol.4 (5), p.433-434

2002

Volltextzugriff (PDF)

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes

Blood, 2005-03, Vol.105 (5), p.1898-1904

2005

Volltextzugriff (PDF)

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

The Journal of experimental medicine, 2004-12, Vol.200 (12), p.1623-1633

2004

Volltextzugriff (PDF)

Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation

Transplant infectious disease, 2006-06, Vol.8 (2), p.108-112

2006

Volltextzugriff (PDF)

Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity

Blood, 2002-05, Vol.99 (9), p.3179-3187

2002

Volltextzugriff (PDF)

Dexamethasone effects on creatine kinase activity and insulin-like growth factor receptors in cultured muscle cells

Journal of cellular physiology, 1989-07, Vol.140 (1), p.8-17

1989

Volltextzugriff (PDF)

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma

The Journal of immunology (1950), 2005-11, Vol.175 (9), p.6238-6238

2005

Volltextzugriff (PDF)

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

Blood, 2003-03, Vol.101 (5), p.1905-1912

2003

Volltextzugriff (PDF)

Characterization of atrial natriuretic peptide receptors in brain microvessel endothelial cells

Journal of cellular physiology, 1991-01, Vol.146 (1), p.43-51

1991

Volltextzugriff (PDF)

Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma

The Journal of immunology (1950), 2005-09, Vol.175 (6), p.4137-4147

2005

Volltextzugriff (PDF)

Autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for the treatment of persistent active EBV infection

Blood, 2002-12, Vol.100 (12), p.4059-4066

2002

Volltextzugriff (PDF)

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease

Journal of immunotherapy (1997), 2004-07, Vol.27 (4), p.317-327

2004

Volltextzugriff (PDF)

Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy

Journal of immunotherapy (1997), 2003-05, Vol.26 (3), p.241-256

2003

Volltextzugriff (PDF)

1 – 25 von 225

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(211)
Mit Volltextzugriff
(186)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation

Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor

T-Cell Immunotherapy for Adenoviral Infections of Stem-Cell Transplant Recipients

Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines

Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo

Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

Immunotherapy for Hodgkin's disease

Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15

Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes

Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients

Options for T-cell based therapies

Immune therapy for EBV infections after hemopoietic stem-cell transplant

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation

Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity

Dexamethasone effects on creatine kinase activity and insulin-like growth factor receptors in cultured muscle cells

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

Characterization of atrial natriuretic peptide receptors in brain microvessel endothelial cells

Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma

Autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for the treatment of persistent active EBV infection

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease

Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy

Suchergebnisse filtern